IDE-397 is a small molecule commercialized by Ideaya Biosciences, with a leading Phase II program in Non-Small Cell Lung Cancer;Squamous Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 3 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of IDE-397’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for IDE-397 is expected to reach an annual total of $47 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
IDE-397 Overview
IDE397 is under development for the treatment of solid tumor, non-small cell lung cancer, pancreatic cancer, squamous non-small cell lung cancer ,adenoid cystic carcinoma (ACC), thymic cancer, colorectal cancer, esophagogastric, bladder and urothelial cell cancer. They act by targeting MAT2A (methionine adenosyltransferase 2A) in tumor cells having MTAP gene deletion. The drug candidates are developed based on synthetic lethality drug discovery platform. It is administered through oral route.
The drug candidate was also under the development of head and neck cancer.
Ideaya Biosciences Overview
Ideaya Biosciences (Ideaya) is a precision medicine company that develops oncology therapeutics. The company’s product pipeline includes darovasertib (IDE196), a protein kinase C (PKC) inhibitor that targets cancers with GNAQ and GNA11 mutations. Ideaya develops small molecule inhibitors based on synthetic lethality against known and novel targets. It also provides solutions for treating tumors with genetic mutations in homologous recombination deficiency(HRD) and high microsatellite instability (MSI). Ideaya is headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$23.4 million for the fiscal year ended December 2023 (FY2023), a decrease of 54.1% over FY2022. The operating loss of the company was US$134.4 million in FY2023, compared to an operating loss of US$62.5 million in FY2022. The net loss of the company was US$113 million in FY2023, compared to a net loss of US$58.7 million in FY2022.
For a complete picture of IDE-397’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
